Even because the nation faces the Covid-19 problem, the World Health Organisation (WHO) has cited inadequate knowledge and rejected the proposal of Pune-based Serum Institute of India (SII) looking for extension of the shelf lifetime of Oxford-AstraZeneca Covid-19 vaccine – Covishield – from six to 9 months.
Sources, who confirmed the event on this regard, mentioned the WHO has additionally sought a gathering with the Drugs Controller General of India (DCGI) to debate the matter. This comes even because the DCGI has prolonged the shelf lifetime of Covishield, developed by Oxford University and Swedish-British pharma main AstraZeneca, from six to 9 months from its manufacturing date.
The WHO had in a current communique to the Serum Institute of India additionally requested the agency to formulate the doses with sufficient titer and/or implement a better specification at launch in order that the minimal specification of two.5 x 108 ifu/dose is fulfilled all through the shelf life, PTI reported.
Earlier in February, India’s drug regulator had written to the Serum Institute of India stating it has no objection in respect of extension of shelf lifetime of Covishield vaccine in a multi-dose glass vial (10 dose-5ml) from six months to 9 months.
The shelf-life, the size of time for which an merchandise stays match to be used, of the AstraZeneca COVID-19 vaccine is six months, as per an replace by the UK drug regulator earlier in February.